Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews

Vista sencilla de ítem
dc.contributor.authorSalazar, Josefina
dc.contributor.authorPerez-Bracchiglione, Javier
dc.contributor.authorSalas-Gama, Karla
dc.contributor.authorAntequera, Alba
dc.contributor.authorAuladell-Rispau, Ariadna
dc.contributor.authorDorantes-Romandı, Rosario
dc.contributor.authorMeade, Adriana G.
dc.contributor.authorQuintana, María Jesús
dc.contributor.authorRequeijo, Carolina
dc.contributor.authorRodrıíguez-Grijalva, Gerardo
dc.contributor.authorSantero, Marilina
dc.contributor.authorAcosta-Dighero, Roberto
dc.contributor.authorSola, Iván
dc.contributor.authorUrrútia, Gerard
dc.contributor.authorBonfill Cosp, Xavier
dc.date.accessioned2022-11-30T02:46:47Z
dc.date.available2022-11-30T02:46:47Z
dc.date.issued2021
dc.description.abstractBackground: Patients with advanced pancreatic cancer (PC) have a high risk of dying in the short or medium-term. This overview aimed to assess the evidence regarding systemic oncological treatments (SOT) versus supportive care for advanced PC. Methods: We searched for systematic reviews (SRs) in MEDLINE, Embase, The Cochrane Library, Epistemonikos, and PROSPERO. Two authors assessed eligibility independently. Data extraction and methodological quality assessment were conducted by one author and cross-checked by another one. We evaluated the overlap of primary studies, performed a de novo meta-analysis, and assessed the certainty of evidence. Primary outcomes were overall survival (OS), quality of life (QoL), functional status (FS), and toxicity. Results: We identified three SRs that assessed SOT versus supportive care in patients with advanced PC. All SRs had critically low methodological quality. At 12 months, OS improved with chemotherapy, radiotherapy followed by chemotherapy, and immunotherapy, but the certainty of the evidence supporting these findings is very low. The evidence on chemotherapy is very uncertain about its effects on QoL; it suggests a slight increase in toxicity and little to no difference in FS. The evidence on immunotherapy is very uncertain about its effects in toxicity. Conclusions: The identified evidence is very uncertain about the benefits of oncological treatments on OS and QoL in patients with advanced PC with a high risk of dying in the short or medium-term, so its use should be proposed only to selected patients. Further studies that include a thorough assessment of patient-centred outcomes are needed.en_ES
dc.facultadFacultad de Medicinaen_ES
dc.file.namePerez_Effic2021.pdf
dc.identifier.citationSalazar J, Pérez-Bracchiglione J, Salas-Gama K, et al. Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews. Eur J Cancer. 2021;154:82-91. doi:10.1016/j.ejca.2021.05.034en_ES
dc.identifier.doihttps://doi.org/10.1016/j.ejca.2021.05.034
dc.identifier.urihttp://repositoriobibliotecas.uv.cl/handle/uvscl/7493
dc.languageen
dc.publisherElsevier
dc.sourceEuropean Journal of Cancer
dc.subjectANTINEOPLASTIC AGENTSen_ES
dc.subjectIMMUNOTHERAPYen_ES
dc.subjectPANCREATIC NEOPLASMSen_ES
dc.subjectREVIEW LITERATURE AS TOPICen_ES
dc.titleEfficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews
dc.typeArticulo
uv.departamentoCentro Interdisciplinario de Estudios en Salud (CIESAL)
uv.notageneralNo disponible para descarga

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Perez_Effic2021_noaccesible_.pdf
Tamaño:
1.15 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Colecciones

Artículos investigadores UV